ALEXA NACEANCENO: Open Payments
NPI 1952867731 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,606 in 87 payments from 30 companies in 2025. Trend: 2023 $2,434 · 2024 $1,422 · 2025 $1,606
Food & beverage: $1,606
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $170 |
| Dexcom, Inc. | 17 | $165 |
| Madrigal Pharmaceuticals | 5 | $104 |
| Lilly USA, LLC | 5 | $87 |
| Novartis Pharmaceuticals Corporation | 4 | $83 |
| Corcept Therapeutics | 4 | $82 |
| Amgen Inc. | 4 | $74 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| SANOFI-AVENTIS U.S. LLC | 2 | $61 |
| BETA BIONICS, INC. | 3 | $58 |
Products named: Dexcom G6 Transmitter, REZDIFFRA, MOUNJARO, Ozempic, LEQVIO, Korlym, TZIELD, iLet Bionic Pancreas.
Industry payments across MO — which companies pay providers there.
